CrestPoint Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

CrestPoint Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-900	Closed	-$349K	–	232
2017 Q1	$349K	Sell	900 -200	-18%	-$74.1K	0.17%	169
2016 Q4	$404K	Buy	1,100 +100	+10%	+$38K	0.2%	157
2016 Q3	$402K	Buy	+1,000	New	+$401K	0.21%	155
2014 Q4	–	Sell	-900	Closed	-$324K	–	227
2014 Q3	$324K	Sell	900 -200	-18%	-$67K	0.2%	162
2014 Q2	$311K	Hold	1,100	–	–	0.18%	163
2014 Q1	$330K	Buy	+1,100	New	+$339K	0.21%	155

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

CrestPoint Capital Management's REGN Position: Q2 2017 in Review

CrestPoint Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2017, closing a stake of 900 shares — an estimated $349K sold.

CrestPoint Capital Management first reported a position in REGN in Q1 2014 and held it in 6 quarters. The position peaked at $404K in Q4 2016. 603 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

CrestPoint Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
CrestPoint Capital Management sold 900 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $349K.
CrestPoint Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 6 quarters.
CrestPoint Capital Management's Regeneron Pharmaceuticals position peaked at $404K in Q4 2016.
603 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on CrestPoint Capital Management's 13F filing for Q2 2017, filed 17 Jul 2017.